

### BASG/AGES MEA

### Federal Office for Safety in Health Care (BASG) and Austrian Medicines and Medical Devices Agency (AGES MEA)

The Federal Office for Safety in Health Care (BASG) and the Austrian Medicines and Medical Devices Agency (AGES MEA) were both set up in January 2006. The BASG is directly subordinated to the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection (BMSGPK), carrying out sovereign tasks, including authorisation and control of medicinal products and vigilance of medical devices.

BASG consists of three members appointed by the Federal Minister of Health, one member from BMSGPK and from AGES MEA each. The third member is the head of the AGES MEA.

AGES MEA is therefore closely linked to the BASG, constituting two of its members, providing BASG with necessary resources, staff and infrastructure. When carrying out sovereign activities, the employees of AGES MEA are acting on behalf of BASG.

Responsibilities of AGES MEA include providing Scientific Advice, inspection in accordance with GMP, GLP and GCP, Clinical Trial Authorisation, assessing dossiers for new marketing authorisations of medicinal products, as well as european surveillance of medicinal products and medical devices already marketed, in terms of efficacy and possible side effects, i.e. pharmacovigilance, and all processes related to Lifecycle-Management. AGES MEA is also monitoring blood-and tissuevigilance issues.



### VALUES OF AGES MEA









**RESPONSIBLE** 

OBJECTIVE

COMPETENT


EUROPEAN

### SCIENTIFIC ADVICE

#### Scientific advice for applicants

When developing medicines, pharmaceutical companies have the possibility of obtaining scientific advice. Both types of procedures (EMA Scientific Advice/National Scientific Advice)

# Number of EMA Scientific Advice Procedures




represent defined focal points for AGES MEA and it covers requests from the area of new substances (chemical and biological), but also from the development of biosimilars and generics. AGES MEA is consistently ranked among the leading medicines agencies within the EU. With to the number scientific advice 2nd procedures it holds place top-position among agencies. achievement impressively illustrates extensive know-how available for applicants customers of AGES MEA to benefit from

2

### **CLINICAL TRIALS**

### Authorisation of clinical trials with medicinal products




#### Commercial vs. non-commercial trials in AT



# CORE COMPETENCES OF AGES MEA

### Approval procedure - Key areas of focus

AGES MEA carries out the scientific assessment of the quality preclinical and clinical data of the marketing authorization application. This assessment determines the outcome of the decision on the approval of a medicinal product. In recent years, the focus has been on the approval of both generic and biotechnological drugs. Blood- and plasma products, vaccines, monoclonal antibodies (MAbs), biosimilars and the field of immunology are AGES MEA's core competencies.



# **AUTHORISATION** AND LIFECYCLE-MANAGEMENT OF MEDICINAL PRODUCTS

AGES MEA plays a sustained and leading role as Rapporteur in the Centralised Procedure (CP) and as Reference Member State (RMS) in the evaluation of Mutal Recognition and De-Centralised authorisation Procedures (MRP/DCP). For years now, Austria has been in the EU Top 10 in MR-/DC-procedures. Since 2009 Austria has constantly occupied a top ten position in benchmarking of European national competent authorities. Recently Austria also entered Top ten in centralised procedures. This achievement clearly underlines the obvious commitment of the Austrian medicines authority to be at the forefront of helping to shape matters at a European level - both in the interest of applicants and of public health.



"Austria has been in the EU Top 10 in MR-/DC-procedures since 2009"


#### **Centralised Procedure**






#### MR-/DC-procedures





Fast processing, time kept as short as possible, many DCP procedures can be finalised before day 210



# SURVEILLANCE


#### **Market surveillance of Medicinal Products**

### **New Marketing Authorisations**



Marketing authorisations issued over the last years national vs. MRP/DCP


■ Proced . MRP & DCP ■ Proced. nat. ■ Sum of procedures finalised



**GM(D)P Inspections** 

# **Authorisations and Variations**


■ Marketing Authorisations ■ Variations (single applications)




New Marketing Authorisations vs. Variations

32.232


Numbers of national and 3rd country GM(D)



### **OMCL**



Approval of plasma pools 2009-2023



Batch Release of vaccines and Plasma derived medicinal products 2007-2023

2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

■ Batch Release of Plasma derived medicinal product

■ Batch Release of Vaccines

# CONTACT

#### **BASG & AGES MEA**

BASG - Federal Office for Safety in Health Care AGES MEA - Austrian Medicines and Medical Devices Agency Traisengasse 5, 1200 Vienna

Head of AGES MEA, Procedural Member of BASG Dipl.-Ing. Dr. Günter Waxenecker basg\_anfragen@ages.at +43 (0) 50 555-36000

Grafikdesign: Valerie Merl / wienergrafik.at Diagramme: Petra Perger / petraberger.at

Cover: Quelle bei Stockfoto

10

